Year 2011

The 2011 Drug Patent ‘Cliff’ And The Evolution Of IP Valuation

In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how to recognise the true value of a firm’s intellectual property. Companies are realising that simply accumulating patents does not necessarily increase their firms’ value, but it is how those patents are used that can attract capital. And drug companies facing massive numbers of upcoming patent expiries, a deflated economy and other market pressures, are looking to diversify their portfolios to stay in the black.

IP & Traditional Cultural Expressions: An Unnatural Alliance?

Incorporating traditional cultural expressions into an intellectual property system will be an uphill battle, warned a panellist at a recent side event at the World Intellectual Property Organization. But, argued another, it could be one of the best ways for indigenous communities to benefit from their knowledge.

Patent On AIDS Medicine Denied In India; Seen Unlocking Market

A decision by the Indian Patent Office to reject a patent on an AIDS drug last week has drawn acclaim from civil society and Indian generic pharmaceutical industries. The decision was not based on a controversial article of Indian law aimed at preventing patent extensions but rather on the grounds of non-inventiveness. Abbott Laboratories, meanwhile, presented Intellectual Property Watch with justification for its Indian patent request.

Net Censorship Fears As Hungary Takes EU Presidency

An internet civil liberties group in Hungary has warned that the country's new media law gives the government censorship authority, threatening freedom of speech and independent journalism. The law took effect on 1 January - at the same time Hungary assumed the six-month presidency of the European Union, raising fears of EU level spread of such policies.